DAUNOTEC 20MG INJECTION is used for inducing remissions of acute myelogenous and lymphocytic leukaemias and for the management of acute lymphocytic leukaemia and acute myloid leukaemia in children, as part of a combination regimen. DAUNOTEC 20MG INJECTION contains Daunorubicin which belongs to the group of medicines known as Chemotherapeutic agents. It works by attacking and destroying the abnormal white blood cells which are present in the person with leukaemia.
DAUNOTEC 20MG INJECTION is not recommended in patients who are recently exposed to, or with existing, chicken pox or herpes zoster, persistent myelosuppression, have severe infection, severe hepatic or renal function impairment. DAUNOTEC 20MG INJECTION should be used with caution if you had radiation therapy for the chest, have or had gout. Consult your doctor for advice before receiving the medicine. DAUNOTEC 20MG INJECTION should not be used during pregnancy unless the clinical condition of the woman requires treatment with DAUNOTEC 20MG INJECTION and justifies the potential risk to the foetus. It is not recommended for use in breastfeeding women.
Your doctor will administer the right dose depends on your child’s age, body weight and severity of the disease. DAUNOTEC 20MG INJECTION should be used with caution in elderly patients with inadequate bone marrow reserves to old age. The most common side effects of receiving DAUNOTEC 20MG INJECTION are nausea, vomiting or diarrhoea. If any of these side effects worsen, contact your doctor immediately.
No content available
